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Drug resistance is amajor challenge to the effective treatment
of cancer. We have developed two nanoparticle formulations,
cationic liposome-polycation-DNA (LPD) and anionic lipo-
some-polycation-DNA (LPD-II), for systemic co-delivery of
doxorubicin (Dox) and a therapeutic small interfering RNA
(siRNA) to multiple drug resistance (MDR) tumors. In this
study, we have provided four strategies to overcome drug resis-
tance. First, we formed the LPD nanoparticles with a guani-
dinium-containing cationic lipid, i.e. N,N-distearyl-N-methyl-
N-2-(N-arginyl) aminoethyl ammonium chloride, which can
induce reactive oxygen species, down-regulate MDR trans-
porter expression, and increase Dox uptake. Second, to block
angiogenesis and increase drug penetration, we have further
formulated LPD nanoparticles to co-deliver vascular endothe-
lial growth factor siRNA andDox. An enhancedDox uptake and
a therapeutic effectwere observedwhen combinedwith vascular
endothelial growth factor siRNA in the nanoparticles. Third, to
avoid P-glycoprotein-mediated drug efflux, we further designed
another delivery vehicle, LPD-II, which showed much higher
entrapment efficiency of Dox than LPD. Finally, we delivered a
therapeutic siRNA to inhibit MDR transporter. We demon-
strated the first evidence of c-Myc siRNA delivered by the
LPD-II nanoparticles down-regulating MDR expression and
increasing Dox uptake in vivo. Three daily intravenous injec-
tions of therapeutic siRNA and Dox (1.2 mg/kg) co-formulated
in either LPD or LPD-II nanoparticles showed a significant
improvement in tumor growth inhibition. This study highlights
a potential clinical use for the multifunctional nanoparticles
with an effective delivery property and a function to overcome
drug resistance in cancer. The activity and the toxicity of LPD-
and LPD-II-mediated therapy are compared.
The occurrence of drug resistance is a main impediment to
the success of cancer chemotherapy. Cancer cells develop dif-
ferent ways to be resistant to chemotherapy drugs. Overexpres-
sion of drug transporter proteins, such as P-glycoprotein
(P-gp)2 plays a key role in regulating drug resistance. Develop-
ment of strategies to down-regulate the expression of P-gp or
inhibit P-gp function has been the major subject of cancer
research. For example, one of the strategies to overcome MDR
is to use carriers like nanoparticles to avoid P-gp-mediated drug
efflux. Only the drug presenting in the cell membrane can be
effluxed out of the cancer cell. The drug delivered by nanopar-
ticles is internalized in the cytoplasm or the lysosome and not
pumpedout by P-gp (1).Dox-loaded liposomes are able to over-
comeMDR by increasing Dox uptake in the nuclei and extend-
ing retention in the nuclei of the MDR cells (2, 3).
Small interfering RNA (siRNA) is a promising novel
approach of cancer therapy. It offers a new strategy to down-
regulate the targeted oncogene for therapeutic intervention.
Systemically delivering siRNA to tumors remains a major hur-
dle in cancer gene therapy (4, 5). Major problems of siRNA
delivery include poor cellular uptake, low stability, and rapid
clearance from the systemic circulation. We have developed a
cationic lipid containing both a guanidinium and a lysine resi-
due as a cationic head group that can down-regulate mitogen-
activated protein kinase (MAPK) signaling, form cationic lipo-
some-polycation-DNA (LPD) to intravenously deliver siRNA
to the solid tumor in high efficiency, and achieve a synergistic
therapeutic effect with siRNA on a human lung cancer model
(6). In this study, we further explored the biological activity of
the guanidinium-containing cationic lipid, i.e. N,N-distearyl-
N-methyl-N-2-(N-arginyl) aminoethyl ammonium chloride
(DSAA),whichmayplay a role in overcoming drug resistance in
tumors. However, nanoparticles containing cationic lipid such
as DSAA showed a poor entrapment efficiency of Dox and
induced immunotoxicity in mice.
To combat these problems, we have further developed the
multifunctional LPD-II nanoparticles made with anionic lipids
that co-deliver siRNA and Dox into the MDR tumor cells and
trigger a synergistic anti-cancer effect. We co-formulated
siRNA and Dox in the LPD-II nanoparticles via Dox intercala-
tion into the DNA in the nanoparticles. Both LPD and LPD-II
nanoparticles were targeted specifically to the tumor cells by
modification with anisamide (AA), a ligand of sigma receptor
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overexpressed in many human cancer cells. Two different
siRNAs, VEGF and c-Myc siRNAs, are selected in this study to
achieve the enhanced drug uptake and anti-cancer effect. We
hypothesized that therapeutic siRNAs delivered to the MDR
cells will down-regulate the target genes and sensitize the
tumor cells to the co-delivered Dox, resulting in an enhanced
therapeutic activity of the nanomedicine. The experiments




anolamine, and cholesterol were purchased from Avanti Polar
Lipids, Inc. (Alabaster, AL). Protamine sulfate (fraction X from
salmon) and calf thymus DNA were purchased from Sigma-
Aldrich (St. Louis, MO). Dox was purchased from IFFECT
CHEMPHAR (Hong Kong). Synthetic 19-nucleotide RNAs
with 3-UU overhangs on both sequences were purchased from
Dharmacon (Lafayette, CO). For quantitative studies, FITC or
cy5.5 was conjugated to 5 sense sequence. 5-cy5.5- and
5-FITC-labeled siRNA sequences were also obtained from
Dharmacon. The sequence of c-Myc siRNA was 5-AACGUU-
AGCUUCACCAACAUU-3, and the VEGF siRNA was 5-
GCAGAAUCAUCACGAAGUG-3. The sequence of control
siRNA with sequence 5-AATTCTCCGAACGTGTCA-
CGT-3 was obtained from Dharmacon.
Synthesis of DSAA—DSAA is a nonglycerol-based guanidine
head group containing cationic lipid synthesized in five steps.
N-Alkylation by n-octadecyl bromide and subsequent Boc
deprotection of mono-Boc-protected ethylene diamine yielded
the mixed primary tertiary amine N1,N1-dioctadecylethane-
1,2-diamine. Tri-N-tert-butoxycarbonyl protected arginine
conjugation to the primary amine group by the conventional
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. Quaterniza-
tion of the tertiary amine group using methyl iodide on the
above obtained product gave tri-N-tert-butoxycarbonyl-pro-
tected DSAA. To obtain the final product DSAA, Boc group
deprotection with trifluoroacetic acid and chloride ion
exchange with Amberlyst A 27(Cl) ion exchange resin were
carried out. The resulting compound was characterized by
using 1H NMR spectra and liquid secondary ion mass spec-
trometry. Detailed synthetic procedures and spectral and
purity data will be delineated elsewhere.3
Cell Culture—NCI/ADR-RES and OVCAR-8 cells were a
kind gift from Dr. Russell Mumper (University of North Caro-
lina School of Pharmacy). NCI-ADR/RES is a multidrug-resis-
tant ovarian cancer cell line derived from OVCAR-8 cells
(drug-sensitive line) in a poorly documented manner (NCI,
National Institutes of Health web site). NCI/ADR-RES cells
were maintained in Dulbecco’s modified Eagle’s medium high
glucose with GlutaMAX (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (Invitrogen), 100 units/ml
penicillin, and 100 g/ml streptomycin (Invitrogen).
Experimental Animals and Tumor Model—Female athymic
nudemice 6–8 weeks of age were purchased from theNational
Cancer Institute, Frederick, National Institutes of Health. The
mice were injected subcutaneously in the right flank with 5 
106 NCI/ADR-RES cells in 0.1 ml of PBS. All of the work per-
formed on animals was in accordance with and permitted by
the University of North Carolina Institutional Animal Care and
Use Committee.
Functional Expression of P-gp—Calcein-AMhas been used as
a functional probe for the detection of P-gp activity (7). The
cells were treatedwith lipids and incubatedwith 1mol/liter of
calcein-AM for 15 min at 37 °C in Dulbecco’s modified Eagle’s
medium. The cells were resuspended in calcein-AM-free
medium, washed twice in PBS, and analyzed using flow cytom-
etry. The uptake calcein-AM in the cells was expressed as: folds
of untreated  (MFItreatment  MFIunstained)/(MFIuntreated 
MFIunstained).
Analysis of ROS—NCI/ADR-RES cells (1  106/well) were
seeded into 12-well plates. The cells were treated with lipids in
serum-containing medium at 37 °C. Then the cells were incu-
bated with 20 M DCFH-DA (Sigma-Aldrich) in serum-con-
taining medium for 30 min at 37 °C. The cells were quickly
washed and immediately analyzed by flow cytometry.
Preparation of Nanoparticle Formulations—LPD nanopar-
ticles were prepared according to the previously described
method with slight modifications (8). Briefly, cationic lipo-
somes composed of cholesterol and DOTAP or DSAA (1:1
molar ratio) were prepared by thin film hydration followed by
membrane extrusion to reduce the particle size. 15 l of prot-
amine (2 mg/ml), 140 l of deionized water, and 24 l of a
mixture of siRNA and calf thymus DNA (2 mg/ml) were mixed
and kept at room temperature for 10 min before adding 120 l
of cationic liposome (20 mM). The formulations stand at room
temperature for 10 min before the addition of DSPE-PEG. The
formulations were then mixed with 70 l of DSPE-PEG or
DSPE-PEG-AA (10mg/ml) and kept at 50–60 °C for 10min for
the attachment of the PEG chains to the surface membrane of
the nanoparticles.
Preparation of PEGylated LPD-II Formulations—LPD-II was
prepared according to the previously described method with
slightmodifications (9). Briefly, anionic liposomes composed of
DOPA, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, and
cholesterol (2:1:1 molar ratio) were prepared by thin film
hydration followed by membrane extrusion to reduce the par-
ticle size. To prepare LPD-II, 48 l of protamine (2 mg/ml), 60
l of deionized water, and 24 l of a mixture of siRNA and calf
thymus DNA (2 mg/ml) were mixed and kept at room temper-
ature for 10 min before adding 90 l of anionic liposome (20
mM). LPD-II was left at room temperature for 10min before the
addition of DSPE-PEG. It was then mixed with 54 l of DSPE-
PEG orDSPE-PEG-AA (10mg/ml) and kept at 50–60 °C for 10
min for the attachment of the PEG chains to the surface mem-
brane of the nanoparticles.
Transmission Electron Microscopy (TEM) Image—TEM
images of the LPD-II nanoparticles were acquired by the use of
JEOL 100CX II TEM (JEOL, Japan). Briefly, 5 l of LPD-II
nanoparticles was dropped on to a 300 mesh carbon coated
copper grid (Ted Pella, Inc., Redding, CA). Excess sample was
removed by blotting with a filter paper. The grid was air-dried
and viewed in TEM without staining. The scale bar was auto-
matically shown in the image according to the magnification.3 S. R. Bathula, Y. Chen, and L. Huang, unpublished observations.
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Cellular Uptake Study—NCI/ADR-RES cells (1  105/well)
were seeded in 12-well plates (Corning Inc., Corning, NY) 12 h
before experiments. The cells were treated with different for-
mulations at a concentration of 250 nM for 5-FITC-labeled
siRNA or 1.5 MDox in serum-containingmedium at 37 °C for
4 h. The cells were washed twice with PBS, counterstained with
DAPI, and imaged using a Leica SP2 confocal microscope. Dox
and siRNAuptake of NCI/ADR-RES cells was alsomeasured by
flow cytometry. Briefly, the cells were treated with different
formulations at a concentration of 250 nM 5-FITC-labeled
siRNA or 1.5 MDox in serum-containingmedium at 37 °C for
1 h. The cells were harvested and resuspended at a concentra-
tion of 1  106 cells/ml. The cells were washed with PBS and
analyzed for fluorescence by flow cytometry.
Gene Silencing Study—NCI/ADR-RES tumor-bearing mice
(tumor size, 1 cm2) were intravenously injected with siRNA
and Dox in different formulations (1.2 mg of siRNA/kg, one
injection/day for 2 days). A day after the third injection, the
tumors were collected, paraffin-embedded, and sectioned.
7.25-m-thick sections were immunostained with primary
antibodies and visualized by using kits from DakoCytomation.
The samples were imaged by using a Nikon Microphot SA
microscope or Leica SP2 confocal microscope.
Quantitative Reverse Transcription-PCR—NCI/ADR-RES
tumor-bearing mice (tumor size, 1 cm2) were intravenously
injected with siRNA and Dox in different formulations (1.2 mg
of siRNA/kg, one injection/day for 2 days). A day after the third
injection, the mice were killed, and tumor samples were col-
lected. Total RNA were extracted with the RNeasy mini kit
(Qiagen, Valencia, CA) by following the manufacturer’s proto-
col. cDNA was then prepared in the presence of reverse tran-
scriptase (Promega, Madison, WI). The mRNA levels were
determined by an ABI PRISMHT7500 sequence detection sys-
tem (Applied Biosystems, Foster City, CA) as described previ-
ously (10). The oligomer pairs used for the amplification of PCR
products were AAGCCACAGCATACATCC (forward primer
for c-Myc), TTACGCACAAGAGTTCCG (reverse primer for
c-Myc), CACCACCAACTACTTAGC (forward primer for
glyceraldehyde-3-phosphate dehydrogenase), and GTAGAG-
GCAGGAATGATG (reverse primer for glyceraldehyde-3-
phosphate dehydrogenase).
Western Blot Analysis—NCI/ADR-RES tumor-bearing mice
(tumor size, 1 cm2) were intravenously injected with siRNA
and Dox in different formulations (1.2 mg of siRNA/kg, one
injection/day for 2 days). A day after the third injection, the
mice were killed, and the tumor samples were collected. Total
protein (40 g) isolated from the tumors was loaded on a poly-
acrylamide gel. Tumor lysates were separated on a 10% acryl-
amide gel and transferred to a polyvinylidene difluoride mem-
brane. The membranes were blocked for 1 h in 5% skim milk
and then incubated with polyclonal antibody against c-Myc
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) overnight.
The membranes were washed in PBST (PBS with 0.1% Tween
20) three times and then incubated for 1 h with the secondary
antibody. The membranes were washed four times and then
developed by an enhanced chemiluminescence system accord-
ing to the manufacturer’s instructions (PerkinElmer Life Sci-
ences, Waltham, MA). The intensity of the bands was quanti-
fied by Photoshop histogram.
Tumor Uptake Study—Mice with a tumor size of 1 cm2
were intravenously injected with cy5.5-labeled siRNA (1.2
mg/kg) andDox (1.2mg/kg) in different formulations. 4 h later,
themicewere killed, and the tissueswere collected, fixed in 10%
formalin, and embedded in paraffin. The tumor tissues were
sectioned (7.25 m thick) and imaged using a Leica SP2 confo-
cal microscope.
TdT dUTP Nick End Labeling (TUNEL) Assay—TUNEL
stainingwas performed as recommendedby themanufacturer’s
protocol (Promega,Madison,WI).NCI/ADR-RES tumor-bear-
ing mice were given intravenous injections of the siRNA and
Dox formulated in the nanoparticles. 24 h after the second
injection, the mice were sacrificed, and the tumors were col-
lected for TUNEL staining. Images from TUNEL-stained
tumor sections were captured with Nikon ECLIPSE Ti-U
microscopy.
Tumor Growth Inhibition Study—NCI/ADR-RES tumor-
bearing mice (size, 16–25 mm2) were intravenously injected
with different formulations containing siRNA (1.2 mg/kg) or
Dox (1.2 mg/kg) once/day for 3 days. Tumor size in the treated
mice was measured after treatment.
Statistical Analysis—All of the statistical analyses were per-
formed by Student’s t test. The data were considered statisti-
cally significant when the p value was less than 0.05.
RESULTS
DSAA, a Guanidinium-containing Lipid, Serves as a P-gp
Inhibitor and a Carrier of siRNA and Dox—Our first strategy is
to use a cationic lipid as a P-gp inhibitor aswell as a drug carrier.
To determine whether the cationic lipid containing a guani-
dinium residue overcomes MDR, we first studied the uptake of
Dox in NCI/ADR-RES cells. NCI/ADR-RES cells were treated
with different lipids for different doses. Then cells were treated
with the indicated concentration of free Dox. The structures of
different lipids used in this study were illustrated in Fig. 1A. As
shown in Fig. 1B, incubation with DSAA resulted in a substan-
tial increase inDox accumulation. The lipidswithout guanidine
groups only caused a slight increase in Dox uptake. Besides, we
also evaluated the ability of different lipids to inhibit P-gp using
the calcein-AM assay in the resistant and sensitive cell lines
(Fig. 1C and supplemental Fig. S1). In drug-resistantNCI/ADR-
RES cells, the fluorescence generated from intracellular calcein
significantly increased in a dose-dependent manner when cells
were treated with DSAA. In contrast, DOTAP or the lipids
without guanidinium groups only caused a slight increase in
intracellular calcein fluorescence. However, intracellular cal-
cein fluorescence remained only slightly changed after treat-
ment with 10 or 50 M DSAA for 1 h in the drug-sensitive
OVCAR-8 cells (supplemental Fig. S1).
Because drug-resistant cells treated with DSAA resulted in
significantly enhancedDox uptake and inhibition of P-gp activ-
ity, we further studied the biological functions ofDSAA in some
detail. The guanidinium head group of DSAAmay induce ROS,
which down-regulates P-gp expression in MDR cells (11, 12).
To address this hypothesis, NCI/ADR-RES cells were treated
with DSAA or DOTAP at different doses and further incubated
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with DCFH-DA. The cellular ROS content was detected by
using flow cytometry. As shown in Fig. 1D, DSAA could signif-
icantly generate ROS in NCI/ADR-RES cells 1 h after treat-
ment. However, the cellular ROS content remained unchanged
after treatment with 1, 5, or 10 M DOTAP for 1 h. Further-
more, MDR expression in MDR cells was significantly sup-
pressed after treatment with 10 or 50 MDSAA (77 and 73% of
untreated control, respectively) (Fig. 1E). These results suggest
that ROS induced by DSAA may reverse drug resistance in
NCI/ADR-RES cells by suppressing MDR transporter expres-
sion and activity.
Based on the property ofDSAA to enhanceDox uptake in the
MDR cells, we further used DSAA as a carrier lipid to deliver
Dox and siRNA into NCI/ADR-RES cells. We used AA-tar-
geted LPD nanoparticles containing DSAA to specifically
deliver Dox and siRNA to the NCI/ADR-RES cells, which
express the sigma receptor (data not shown). As shown in
supplemental Fig. S2,A and B), targeted nanoparticles contain-
ing DSAA increased both cellular internalization and nuclear
uptake of Dox compared with free Dox. The nanoparticles con-
taining DSAA delivered Dox into the cytoplasm of NCI/ADR-
RES cells more efficiently than those containing DOTAP. Fur-
thermore, Dox uptake of the cells treated with the targeted
nanoparticles wasmuchmore than that of cells treatedwith the
nontargeted nanoparticles. Pretreatment or co-incubation of
cells with blank-targeted nanoparticles also showed slightly
enhanced Dox uptake compared with free Dox. To eliminate
the possibility that Dox uptake enhancement was due to apo-
ptosis caused by DSAA, the cells were co-incubated with the
caspase-3 inhibitor DEVD-CHO32 and Dox in the targeted
nanoparticles containing DSAA. In this treatment, the uptake
of Dox was as much as the treatment without the caspase-3
inhibitor (supplemental Fig. S2A). The uptake of Dox in the
targeted nanoparticles containing DSAAwas further examined
in the other drug-resistant cells, H460/RES cells, which also
overexpress P-gp. As shown in supplemental Fig. S3, targeted
nanoparticles containing DSAA increased Dox uptake com-
pared with free Dox in H460/RES cells.
To confirm the ability of DSAA to deliver both Dox and
siRNA into NCI/ADR-RES cells, Dox and fluorescently
labeled siRNA were co-formulated into different formulations.
As shown in Fig. 2A, the uptake ofDox and fluorescently labeled
FIGURE 1. Treatment of DSAA-enhanced Dox uptake in NCI/ADR-RES cells by down-regulating MDR expression and activity. A, chemical struc-
tures of cationic lipids. B, quantitative measurement of Dox uptake after 1 h of incubation with different concentrations of cationic lipids by flow
cytometry. C, quantitative measurement of calcein-AM uptake after 1 h of incubation with different concentrations of cationic lipids by flow cytometry.
D, ROS generation by DSAA or DOTAP after 1 h of incubation with different concentrations of DSAA or DOTAP. The ROS content of cells was analyzed by
flow cytometry; n  3. E, MDR expression in NCI/ADR-RES cells after incubation with 10 or 50 M DSAA and DOTAP for 24 h. DSA, N-methyl-N,N-distearyl
ammonium chlolride.
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siRNAwasmuch greater in cells treatedwith the formulation pre-
pared with DSAA than the formulation prepared with DOTAP,
and the uptake was ligand-dependent. Some Dox co-localized
with siRNA in the cytoplasm, and some translocated to the
nucleusafter treatmentofDoxandFITC-siRNAformulated in the
targetednanoparticles containingDSAA.The results indicate that
the nanoparticles containing DSAA efficiently co-delivered
siRNA and Dox to the NCI/ADR-RES cells, and the delivery
was ligand-specific and formulation lipid-dependent.
VEGF siRNA Delivered by Nanoparticles Containing DSAA
Showed SignificantGene Silencing and Enhanced Penetration of
Drugs inNCI/ADR-RESTumor—Our second strategy is to use
a therapeutic siRNA to inhibit angiogenesis and sensitize the
drug-resistant cells to chemother-
apy drugs. To examine the biolog-
ical activities of siRNA co-formu-
lated with Dox in different
formulations in vivo, the VEGF
levels in the subcutaneous NCI/
ADR-RES tumor were detected by
Western blotting 24 h after two
daily intravenous injections of
VEGF siRNA and Dox in different
formulations (Fig. 2B). VEGF
expression of the NCI/ADR-RES
tumor treated with VEGF siRNA
andDox-containing targetednano-
particles was significantly sup-
pressed (45% of untreated control)
(Fig. 2B), whereas VEGF siRNA
and Dox-containing nontargeted
nanoparticles and a control siRNA
and Dox-containing targeted nano-
particles showed no silencing
effect. The results indicate that the
nanoparticles containing DSAA
could systemically deliver siRNA
into the tumor tissue and silence
the target protein. Furthermore,
the silencing effect was specifi-
cally controlled by the targeting
ligand.
To further study the effect of
VEGF siRNA and DSAA on Dox
uptake in vivo, tumor-bearing mice
were given two daily injections of
VEGF siRNA or a control siRNA
(1.2 mg/kg) formulated in the
targeted nanoparticles containing
DSAA or DOTAP. 24 h after the
second treatment, free Dox or Dox
formulated in the targeted nano-
particles containing DSAA was
intravenously injected into tumor-
bearing mice. The Dox uptake of
NCI/ADR-RES tumor tissue in the
tumor-bearing mice was observed
4 h after intravenous injections
using confocal microscopy. As shown in Fig. 2D, Dox formu-
lated in the targeted nanoparticles showed enhanced cytoso-
lic delivery in NCI/ADR-RES cells compared with free Dox.
Free Dox uptake was higher in the tumor tissues collected
from the mice treated with a control siRNA formulated in
the DSAA-containing targeted nanoparticles than in those
from the mice treated with a control siRNA formulated in
the DOTAP-containing targeted nanoparticles. Further-
more, the formulated Dox uptake also increased in the tumor
tissues collected from mice treated with a control siRNA in
the DSAA-containing targeted nanoparticles rather than
those treated with a control siRNA in the DOTAP-contain-
ing targeted nanoparticles (Fig. 2C). These results indicate
FIGURE 2. Intracellular uptake of Dox and siRNA and gene silencing effect in NCI/ADR-RES cells in vitro
and in vivo. A, cells were treated with different formulations containing Dox (red) and siRNA (green) for 2 h and
observed by confocal microscopy. The nuclei are blue (DAPI). B, examination of VEGF expression in NCI/ADR-
RES xenograft tumor using Western blot analysis after treatment with different formulations. C and D, Dox
formulated in the targeted nanoparticles containing DSAA (C) or free Dox (D) was intravenously injected into
the tumor-bearing mice 24 h after the second administration of VEGF or control siRNA in the nanoparticles
containing DSAA or DOTAP. Tumor uptake of Dox in the targeted nanoparticles containing DSAA (C) or free
Dox (D) 4 h after intravenous administration was observed by confocal microscopy. E, MDR expression (green)
in NCI/ADR-RES tumors 24 h after intravenous administrations of different formulations. NCI/ADR-RES tumor-
bearing mice were injected two daily administrations of VEGF or control siRNA (1.2 mg/kg) formulated in the
targeted nanoparticles containing DSAA or DOTAP. NP, nanoparticles.
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that DSAA reverses drug resistance in NCI/ADR-RES
tumors.
VEGF inhibitors such as bevacizumab can enhance the per-
meability of the tumor vasculature, which leads to improved
penetration of the free or liposome-encapsulated chemother-
apy agents in the tumor (13). We hypothesized that VEGF
siRNAmay improve the penetration and uptake of free Dox or
formulated Dox in the drug-resistant tumor. As shown in Fig.
2D, free Dox uptake was higher in the tumor tissues collected
from the mice treated with VEGF siRNA formulated in the
DSAA-containing targeted nanoparticles than in those from
themice treatedwith a control siRNA formulated in theDSAA-
containing targeted nanoparticles. Similarly, the formulated
Dox uptake was also enhanced in the tumor tissues collected
from mice treated with VEGF siRNA in the targeted nanopar-
ticles compared with those treated with a control siRNA in the
targeted nanoparticles (Fig. 2C). These results indicate that the
uptakes of both free and formulated Dox increased after treat-
ment with VEGF siRNA.
To verify the regulatory effects ofDSAAandVEGF siRNAon
the expression ofMDR transporters in vivo,MDR expression in
the drug-resistant tumor was examined by immunostaining
24 h after two daily intravenous injections of VEGF siRNA or a
control siRNA in different formulations (Fig. 2E).MDR expres-
sion of the NCI/ADR-RES tumor treated with VEGF siRNA or
a control siRNA in the targeted nanoparticles containingDSAA
was partially suppressed (Fig. 2E). A control siRNAdelivered by
the targeted nanoparticles containing DOTAP showed no
effect. Thus, the data indicate that inhibition of the MDR
expression mediated by the targeted nanoparticles was formu-
lation lipid-dependent but not siRNA sequence-specific. Taken
together, these results demonstrate a combination effect
between VEGF siRNA and DSAA in promoting Dox uptake in
NCI/ADR-RES tumors. A combination effect between VEGF
siRNA and DSAA in promoting cellular apoptosis and tumor
growth inhibition was further tested.
VEGF siRNA and Dox Co-delivered by Nanoparticles Con-
taining DSAA Showed Significant Therapeutic Effect in NCI/
ADR-RES Tumor—To examine the therapeutic activities of
siRNA andDox in the different formulations, we stained for the
apoptotic markers in NCI/ADR-RES tumors (Fig. 3A). Fig. 3A
indicates that 8% of NCI/ADR-RES cells treated with VEGF
siRNA andDox in the targeted nanoparticles containing DSAA
underwent apoptosis as detected by the TUNEL staining. This
valuewas significantly higher than the cells treatedwith control
siRNA formulated in the targeted nanoparticles containing
DSAA or VEGF or control siRNA formulated in the targeted
nanoparticles containing DOTAP. To further elucidate the
therapeutic effects of Dox and VEGF siRNA in the nanopar-
ticles containing DSAA, tumor growth inhibitory effects were
evaluated after treatments of different formulations. Three
injections of VEGF siRNA alone in the targeted nanoparticles
containing DSAA showed a partial inhibition of tumor growth
(p  0.05 comparing with the untreated control at day 18) (Fig.
3B). Free Dox had no therapeutic effect. A synergistic tumor
growth inhibition was observed when mice were treated with
Dox and VEGF siRNA co-formulated in the targeted nanopar-
ticles containing DSAA. Thus, targeted nanoparticles loaded
with bothVEGF siRNA andDSAA could sensitizeMDR cells to
co-formulated Dox. Furthermore, VEGF siRNA andDox in the
targeted nanoparticles containing DOTAP or in the nontar-
geted nanoparticles containing DSAA showed less therapeutic
effect comparedwith the treatment of VEGF siRNA andDox in
the targeted nanoparticles containing DSAA (Fig. 3C). The
results indicate that the therapeutic effects of the formulations
are both lipid- and ligand-dependent. Taken together, DSAA-
containing targeted nanoparticles loaded with both Dox and
VEGF siRNA could overcome P-gp-mediated drug resistance.
All therapeutic agents in a single formulation worked together
to induce apoptosis and suppress tumor growth by inhibiting
the mechanisms involved in drug resistance and survival.
However, cationic lipids such as DSAA competed with Dox
for interacting with DNA, resulting in a low entrapment effi-
FIGURE 3. Apoptosis induction and growth inhibition in NCI/ADR-RES
xenograft tumor. A, quantitative analysis of TUNEL positive staining in the
NCI/ADR-RES tumors collected after three daily intravenous administrations
of siRNA (1.2 mg/kg) and Dox (1.2 mg/kg) in different formulations; n  3– 6.
The asterisk indicates p  0.05. B, comparison of therapeutic efficacy of VEGF
and control siRNAs co-formulated with Dox in the targeted nanoparticles
containing DSAA. C, comparison of therapeutic efficacy of the targeted and
nontargeted nanoparticles containing DSAA or DOTAP. The arrows indicate
the intravenous administrations of siRNA (1.2 mg/kg) and Dox (1.2 mg/kg).
The data are the mean values; n  4 –5.
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ciency of Dox in the nanoparticles (14). The amount of Dox
loaded into the final formulation was only 10% of the total
Dox determined by Sepharose CL 2B column chromatography.
To solve these problems,wehave employed another gene trans-
fer vector, i.e. LPD-II, composed of anionic lipids instead of
cationic lipids (9). In this case, DNA only interacts with prot-
amine and Dox. We expect that the enhanced entrapment effi-
ciency would be achieved. In the following study, we explored
the potential of LPD-II nanoparticles for the treatment ofMDR
cancer.
LPD-II Nanoparticles Avoided P-gp-mediated Drug Efflux
fromNCI/ADR-RES Cells—The third strategy developed in the
study is to use a carrier, which has the high entrapment effi-
ciency of Dox to avoid P-gp-mediated drug efflux. Only the
drug presenting in the cell membrane can be effluxed out of the
cancer cell. The drug delivered by nanoparticles is internalized
in the cytoplasm or the lysosome and not pumped out by P-gp.
The amount of Dox loaded into the LPD-II nanoparticles was
90% of the total Dox determined by Sepharose CL 2B column
chromatography. TEM images of the PEGylated LPD-II nano-
particles are shown in Fig. 4A. These nanoparticles are well
dispersed spheres with sizes ranging from 20 to 50 nm. As
shown in the confocal micrographs in Fig. 4B, the resulting
nanoparticles efficiently delivered Dox (red) and FITC-labeled
siRNA (green) to the NCI/ADR-RES cells. Dox was located in
the nuclei of the cells, and siRNA was found in the cytoplasm.
Dox and siRNA uptake was further compared among differ-
ent nanoparticle formulations by using flow cytometry. As can
be seen in Fig. 4 (C and D), both siRNA and Dox delivered by
targeted nanoparticles were taken up by NCI/ADR-RES cells
more efficiently than those delivered by nontargeted nanopar-
ticles or free drug. The uptake of Dox in the targeted nanopar-
ticles was further examined in another drug-resistant cell line,
P388/ADR cells, which also overexpressed P-gp. We modified
the nanoparticleswith a tumor targeting peptide that contained
the Asn-Gly-Arg motif, a ligand of CD13 overexpressed in
malignant myeloid leukemia cells such as P388 (15, 16). We
have previously used the same Asn-Gly-Arg peptide to target
siRNA to CD13-expressing cancer cells (14). As shown in
supplemental Fig. S4, targeted nanoparticles increased Dox
uptake compared with free Dox in P388/ADR cells. Thus, tar-
geted LPD-II nanoparticles showed potential to deliver both
siRNAandDox to drug-resistant tumor cells in a target-specific
manner.
We further studied the cy5.5-siRNA (green) and Dox (red)
uptake of NCI/ADR-RES tumor tissue in the tumor-bearing
mice 4 h after intravenous injections using confocal micros-
copy. As shown in Fig. 4E, the intracellular fluorescence signals
were hardly detected in the tumor tissues collected from mice
treated with nontargeted nanoparticles or free drug. The tar-
geted nanoparticles showed strong cytosolic delivery of
cy5.5-siRNA and nuclear delivery of Dox in the tumor tissue.
Part of Dox co-localized with siRNA (yellow) in the cytoplasm
of the tumor cells. These results indicate that the targeted
nanoparticles could efficiently deliver siRNA and Dox to the
tumor tissue, and the intracellular delivery was dependent on
the presence of the ligand on the nanoparticles.
c-Myc siRNA Delivered by LPD-II Nanoparticles Down-regu-
lated Both c-Myc and MDR Expression and Showed Enhanced
Dox Uptake in NCI/ADR-RES Tumor—The last strategy we
presented in this study is to co-deliver Dox and a therapeutic
siRNA to inhibit both the survival signaling and the pathways
that trigger drug resistance inMDR cancer cells. c-Myc, a tran-
scription factor overexpressed in many human cancer cells,
appears to play an important role in the regulation of cell
growth and may activate MDR-1 transcription through the
binding of the E-box motif (CACGTG) localized in the MDR1
gene promoter (272 and 444) (29). Therefore, c-Myc was
chosen as a therapeutic target in the following study. To address
the activities of siRNA in vivo, the c-Myc level in the tumor was
assessed by quantitative reverse transcription-PCR and West-
ern blot analysis (Fig. 5). Both c-Myc mRNA and protein
expressions of the NCI/ADR-RES tumor treated with c-Myc
siRNA and Dox-containing targeted nanoparticles were signif-
icantly inhibited (Fig. 5). c-Myc expression in NCI/ADR-RES
tumor was silenced by c-Myc siRNA delivered with targeted
nanoparticles (40% of untreated control), whereas the non-
targeted nanoparticles and the control siRNA showed no effect.
To verify the regulatory effects of c-Myc on the expression of
MDR transporters (13), the protein levels of MDR transporters
were measured 72 h after transfection of the siRNA targeting
c-Myc. As shown in Fig. 6A, the MDR expression was signifi-
cantly decreased inNCI/ADR-RES cells transfectedwith c-Myc
siRNA compared with those transfected with control siRNA.
To address theMDR down-regulation in vivo, theMDR level in
the tumorwas detected by immunostaining (Fig. 6C). TheMDR
expression of the NCI/ADR-RES tumor treated with c-Myc
siRNA and Dox-containing targeted nanoparticles was signifi-
cantly inhibited (Fig. 6C). Nontargeted nanoparticles and the
control siRNA showed no effect.
To elucidate whether the down-regulation of the c-Myc
expression could reverse the drug resistance of NCI/ADR-RES
cells, Dox uptake was further compared among cells trans-
fected in vitrowith the c-Myc and control siRNAs by using flow
cytometry. As shown in Fig. 6B, free Dox uptake was signifi-
cantly increased inNCI/ADR-RES cells transfected with c-Myc
siRNA compared with those transfected with control siRNA.
We further studied the Dox uptake of NCI/ADR-RES tumor
tissue in the tumor-bearing mice 4 h after intravenous injec-
tions using confocal microscopy. Tumor-bearing mice were
given two daily injections of c-Myc or control siRNA (1.2
mg/kg) formulated in the targeted nanoparticles. As shown in
Fig. 6D, the targeted nanoparticles encapsulating Dox showed
an increased cytosolic delivery of Dox on NCI/ADR-RES cells
compared with free drugs. Free Dox uptake was higher in the
tumor tissues collected from the mice treated with c-Myc
siRNA than themice treatedwith control siRNA. Furthermore,
the formulatedDox uptakewas also slightly higher in the tumor
tissues from mice treated with c-Myc siRNA than in those
treated with control siRNA. These results indicate that the
uptakes of both free and formulated Dox were enhanced after
treatment with c-Myc siRNA in the targeted nanoparticles.
These studies suggest that the down-regulation of c-Myc
expression could reverse the drug resistance of NCI/ADR-RES
cells through the regulation of MDR transporter expression.
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FIGURE 4. Characterization of LPD-II nanoparticles. A, TEM images of PEGylated LPD-II nanoparticles shown in two different magnifications. B, fluorescence
photographs of NCI/ADR-RES cells after treatment with free siRNA (green) (panel a), free Dox (red) (panel b), siRNA and Dox in targeted nanoparticles (panel c),
or nontargeted nanoparticles (panel d) for 1 h. C and D, quantitative measurement of Dox (C) and siRNA (D) uptake in NCI/ADR-RES cells by flow cytometry. The
cells were treated with different formulations containing Dox or FITC-siRNA for 1 h and analyzed for fluorescence by flow cytometry. E, tumor uptake of siRNA
and Dox in different formulations. Fluorescence signal of cy5.5-labeled siRNA and Dox in NCI/ADR-RES tumor was observed by confocal microscopy. The nuclei
are blue (DAPI). NP, nanoparticles.
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c-Myc siRNA and Dox Co-delivered by LPD-II Nanoparticles
Showed Significant Therapeutic Effect in NCI/ADR-RES Tumor—
To examine the apoptosis induced by the nanoparticles in the
MDR tumors, we examined cellular apoptosis by using TUNEL
staining (Fig. 7A). As shown in the figure, the number of
TUNEL-positive cells increased after treatment of c-Myc
siRNA and Dox co-delivered with the targeted nanopar-
ticles. Intravenous injections of c-Myc siRNA and Dox in the
nontargeted nanoparticles or the control siRNA and Dox in
the targeted nanoparticles showed only a slight increase in
TUNEL-positive cells. The level of the active caspase-3 was
further detected by Western blot analysis (Fig. 7B). Activa-
tion of caspase-3 is a common mechanism triggered by fac-
tors that induce apoptosis (17). As shown in Fig. 7B, active
caspase-3 in the NCI/ADR-RES tumor from mice treated
with targeted nanoparticles containing c-Myc siRNA and
Dox was significantly induced compared with those treated
with other control formulations. There was a slight increase
of the active caspase-3 in the tumors from mice treated with
nontargeted nanoparticles or targeted nanoparticles con-
taining Dox and control siRNA compared with the untreated
mice. The results indicate that c-Myc siRNA and Dox
formulated in the targeted nanoparticles could synergisti-
cally promote apoptosis in the NCI/ADR-RES tumor, and
the cell killing effect was siRNA-
and targeting ligand-dependent.
To elucidate the synergistic
effects of Dox and c-Myc siRNA,
tumor growth inhibitory effects
were examined in vivo. Three
injections of control siRNA and
Dox in the targeted nanoparticles
showed a partial inhibition of
tumor growth (p  0.05 compared
with the untreated control at day
18) (Fig. 7C). Other control groups
treated with control siRNA formu-
lated in the targeted nanoparticles
without Dox or free Dox had no
therapeutic effect. The results indi-
cate that Dox formulated in the tar-
geted nanoparticles showed an
enhanced tumor inhibition effect.
Furthermore, three injections of
c-Myc siRNA in the targeted nano-
particles failed to show the thera-
peutic effect (Fig. 7D). c-Myc siRNA
and Dox in the nontargeted nano-
particles showed a partial inhibi-
tion of tumor growth (p  0.05 at
day 18) (Fig. 7D). A significant
tumor growth inhibition was ob-
served when mice were treated
with Dox and c-Myc siRNA co-
formulated in the targeted nanopar-
ticles. Thus, targeted nanoparticles
loaded with both Dox and c-Myc
siRNA could overcome P-gp-medi-
ated drug resistance.
Toxicity Study—In addition to
efficacy, toxicity is another critical
parameter of a suitable delivery
vehicle for clinical use. Therefore,
FIGURE 5. c-Myc expression in NCI/ADR-RES xenograft tumor. Shown is
validation of c-Myc mRNA and protein expression in the NCI/ADR-RES
xenograft tumor using real time PCR (A) and Western blot analysis (B) after
treatment with different formulations. Column a, c-Myc siRNA and Dox co-
formulated in targeted nanoparticles. Column b, c-Myc siRNA and Dox in non-
targeted nanoparticles. Column c, control siRNA and Dox in targeted nano-
particles. NP, nanoparticles.
FIGURE 6. MDR expression in NCI/ADR-RES xenograft tumor. A, MDR expression in NCI/ADR-RES cells 72 h
after transfection of siRNA with Lipofectamine in vitro. B, free Dox uptake in NCI/ADR-RES cells 72 h after
transfection of siRNA with Lipofectamine. The cells were treated with free Dox for 30 min and analyzed for
fluorescence by flow cytometry. The data are the mean values  S.D.; n  3. The asterisk indicates p  0.01.
C, MDR expression (green) in NCI/ADR-RES tumors 24 h after dosing of different formulations (two daily intra-
venous administrations of 1.2 mg/kg siRNA formulated in nanoparticles). D, tumor uptake of free Dox or Dox in
the targeted nanoparticles 4 h after intravenous injection. Fluorescence signal of Dox (red) in NCI/ADR-RES
tumor was observed by confocal microscopy. The nuclei are blue (DAPI). Tumor-bearing mice were given two
daily injections of c-Myc or control siRNA (1.2 mg/kg) formulated in the targeted nanoparticles. Free Dox or Dox
formulated in the targeted nanoparticles was intravenously injected into the tumor-bearing mice 24 h after
the final treatment of siRNA. Panel a, untreated; panel b, c-Myc siRNA in targeted nanoparticles; panel c,
c-Myc siRNA in nontargeted nanoparticles; panel d, control siRNA in targeted nanoparticles; panel e,
intravenous administration of Dox in targeted nanoparticles 24 h after treatment of c-Myc siRNA; panel f,
intravenous administration of Dox in targeted nanoparticles 24 h after treatment of control siRNA; panel
g, intravenous administration of free Dox 24 h after treatment of c-Myc siRNA; h, intravenous administra-
tion of free Dox 24 h after treatment of control siRNA. MFI, mean fluorescence intensity.
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the proinflammatory cytokine (IL-6 and IL-12), hepatotoxicity
maker (alanine aminotransferase and aspartate aminotrans-
ferase) levels, and the hematology parameters in the serum
were examined for evaluation of toxicity induced by the
nanoparticles in C57BL/6 mice (supplemental Table S1).
siRNA and Dox formulated in the targeted LPD-II nanopar-
ticles did not induce IL-6 and IL-12 significantly. Alanine ami-
notransferase and aspartate aminotransferase levels also
remained the same as the untreated animals. Dox and siRNA
formulated in the LPD-II targeted nanoparticles were very well
toleratedwith no significant changes in key hematology param-
eters. However, siRNA and Dox formulated in the targeted
nanoparticles containing DSAA induced a significant produc-
tionof IL-12.As shown in supplementalTable S1, thewhite blood
cell count and platelet count were significantly reduced after
treatment of siRNA andDox in the targeted nanoparticles con-
taining DSAA (LPD). Because treatment of siRNA and Dox in
the LPD-II nanoparticles resulted in significantly enhanced
drug uptake and an anti-cancer effect in MDR tumors without
toxicity, we believe that LPD-II is a valuable lipid carrier for
siRNA and drug delivery against MDR tumors.
DISCUSSION
The occurrence of drug resist-
ance is an important obstacle of
cancer therapy. Drug transporter
proteins, such as those in the MDR
family, are overexpressed in most
drug-resistant cancer cell lines and
recurrent tumors in cancer patients.
Dox is known as a MDR substrate,
and its reduced uptake and com-
promised therapeutic efficacy are
related to MDR overexpression
(18). In this study, our aim was to
develop a multifunctional nanopar-
ticle delivery system that can sys-
temically deliver therapeutic siRNA
and Dox into the drug-resistant
tumors and achieve an enhanced
therapeutic effect. We discuss sev-
eral strategies in one single nano-
particle formulation to improve
drug uptake in the MDR tumors.
First, a guanidinium-containing
cationic lipid, DSAA, was utilized to
form LPD nanoparticles. We first
demonstrated that DSAA induced
ROS, inhibited the activity and
expression of MDR transporters,
and enhanced Dox uptake in NCI/
ADR-RES cells (Fig. 1). However,
cationic lipids without guanidinium
groups did not cause these effects.
Thus, the guanidinium group plays
an important role in determining
the activity of the lipids. It has been
shown that guanidinium com-
pounds generate ROS such as
hydroxyl free radical (OH) (19). The guanidium ion in the head
group of DSAA may donate an electron to generate a superox-
ide-forming hydroxyl radical. Furthermore, it is known that
ROS down-regulates MDR expression by activating c-Jun
N-terminal kinase (JNK) and c-Jun in MDR cells (12, 20). ROS
generated by DSAAmay serve as a secondary messenger in the
receptor tyrosine kinase signaling pathways and result in the
down-regulation of MDR expression. In this study, DSAA
served as both a formulation component to deliver siRNA and
Dox into theMDRcells aswell as a therapeutic agent that inhib-
ited expression of MDR transporters and sensitized MDR cells
to chemotherapy drugs.
Second, we co-delivered VEGF siRNA to target tumor vas-
culature, block angiogenesis, and disrupt local blood supply.
We found an enhanced tumor uptake of free Dox and formu-
lated Dox after the treatment with VEGF siRNA (Fig. 2). Fur-
thermore, an enhanced growth inhibition of NCI/ADR-RES
tumor was observed after co-delivery of VEGF siRNA and Dox
in the targeted nanoparticles containing DSAA. VEGF siRNA
alone or Dox alone in the targeted nanoparticles only achieved
FIGURE 7. Apoptosis induction and growth inhibition in NCI/ADR-RES xenograft tumor. A, quantitative
analysis of TUNEL positive staining in the tumors collected after two consecutive intravenous injections of
siRNA and Dox in different formulations; n  3. The asterisk indicates p  0.05. B, caspase-3 activation in
NCI/ADR-RES tumors 24 h after dosing of different formulations (two daily intravenous administrations of 1.2
mg/kg siRNA and 1.2 mg/kg Dox co-formulated in the nanoparticles). C, comparison of anti-tumor efficacy of
free Dox and Dox delivered by targeted nanoparticles. D, comparison of anti-tumor efficacy of c-Myc siRNA and
control siRNA co-formulated with Dox in different nanoparticles. The arrows indicate the intravenous admin-
istrations of siRNA (1.2 mg/kg) and Dox (1.2 mg/kg). The data are the mean values; n  5–7. The standard
deviations of the data points are not shown for clarity. E, schematic illustration of possible mechanisms to
overcome drug resistance and achieve enhanced therapeutic effect in MDR cells using multifunctional LPD-II
nanoparticles. NP, nanoparticles.
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a partial therapeutic effect. Several mechanisms may be
involved in the anti-cancer effect of anti-VEGF therapy. Anti-
angiogenesis triggered by VEGF siRNA can kill the tumor cells
and sensitize the cells to chemotherapy agents by blocking
blood supply. Furthermore, anti-angiogenic therapy can im-
prove drug penetration as shown in Fig. 2. It may be due to
disruption or normalization of tumor vasculature, which
results in reduced interstitial fluid pressure and enhanced drug
permeability (21–23).
On the other hand, instead of using a cationic formulation
lipid, we developed second generation LPD (LPD-II) nanopar-
ticles that contain a DNA polycation condensed core coated
with an anionic lipid membrane consisting of mainly DOPA.
Our previous study suggested that when the cationic liposomes
interacted with the negatively charged DNA-protamine com-
plex, there was a substantial loss of Dox from the nanoparticle-
associated DNA, and Dox encapsulation in the final LPD nano-
particles was significantly reduced (14). Compared with the
LPD nanoparticles, the current LPD-II nanoparticles made
with anionic lipids could carry more Dox in the formulation.
Third, as illustrated in Fig. 7E, another approach to overcome
drug-resistant cancer is to use a drug delivery vehicle to deliver
Dox and to avoid P-gp-mediated drug efflux. As shown in Fig. 4,
targeted nanoparticles delivered more Dox to NCI/ADR-RES
cells than nontargeted nanoparticles or free Dox. Dox
entrapped in the targeted nanoparticles induced a significantly
increased tumor uptake (Fig. 4) in the NCI/ADR-RES tumor
model. An enhanced therapeutic effectwas achieved by theDox
formulated in the targeted nanoparticle (Fig. 7). The targeted
nanoparticles may avoid P-gp-mediated drug efflux by using
ligand-dependent internalization. The internalized drugs that
cannot “see” the efflux transporter are not pumped out of the
cells. Furthermore, the entrapped Dox may be maintained
for a prolonged period of time in the circulation after intra-
venous administration and taken up more in the tumor tis-
sue compared with the free Dox. The targeted nanoparticles
that selectively deliver Dox to tumor cells can enhance both
the therapeutic efficacy and the safety of the therapeutic
agents.
The last strategy is to silence theMDR expression by siRNA.
Instead of silencing the MDR itself, we chose to silence c-Myc
for two reasons. The first is that c-Myc has been implicated to
positively control MDR expression (24–26). Silencing c-Myc
may result in the down-regulation ofMDR,which appears to be
expressed on plasma membrane and nuclear envelope (27, 28).
The second is that c-Myc is a well known oncogene, the silenc-
ing of which may bring about a direct anticancer effect. In this
study, we demonstrated that c-Myc siRNA delivered by tar-
geted nanoparticles significantly down-regulated both c-Myc
and MDR expressions in NCI/ADR-RES tumor, caused
enhanced Dox uptake, and sensitized drug-resistant tumor
cells to the co-delivered Dox (Figs. 5 and 6). c-Myc, a transcrip-
tion factor overexpressed in many human cancer cells, may
activateMDR-1 transcription through the binding of the E-box
motif (CACGTG) localized in theMDR1 gene promoter (272
and 444) (29). Therefore, inhibition of c-Myc expression by
siRNA results in the down-regulation of the MDR expression.
This strategy is schematically illustrated in Fig. 7E.
We have developed two different but novel nanoparticles to
overcome drug resistance for cancer therapy. The comparisons
between two nanoparticle formulations are listed in Table 1.
Both multifunctional nanoparticle formulations can deliver
Dox and siRNA to MDR tumor simultaneously. The same
amount of siRNA and Dox delivered by targeted LPD and
LPD-II showed similar apoptosis inductions and therapeutic
efficacies in NCI/ADR tumors. However, based on the toxicity
study, LPD nanoparticles containing DSAA induced more tox-
icity compared with LPD-II nanoparticles. The mechanism of
immunotoxicity induced by LPD nanoparticles containing
DSAA may be mediated through the interaction between the
cationic lipid and immune cells (30). In conclusion, LPD-II
nanoparticles with a higher entrapment efficiency of Dox and a
lower toxicity profile may show a larger therapeutic window
and potential clinical application for cancer therapy than the
LPD nanoparticles. To our knowledge, this is the first parallel
preclinical study of systemic co-delivery of therapeutic siRNA
and a chemotherapy drug to a drug-resistant tumor using two
different multifunctional gene delivery systems.
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